
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences is a promising company with a strong intellectual property portfolio, with a potential for significant growth in the retinal medicines market. The positive results from the Phase 3 GLOW2 study for Zenkuda in patients with NPDR and the ongoing DAYBREAK study for wet AMD, along with the company's strategic decision to include Zenkuda in the DAYBREAK study, gives confidence in the long-term potential of both Zenkuda and KSI-501. The company also has a robust pipeline and a strong presence in the retinal medicine space, making it a favorable investment for long-term growth.
Bears say
Kodiak Sciences is a pre-commercial biopharmaceutical company that has developed a proprietary ABC platform for retinal medicines. While Kodiak's investigational medicines show promise in addressing unmet needs in retinal diseases, the company faces significant challenges in bringing its products to market, including competition from other big biopharma companies, potential manufacturing difficulties, and financing risks. These factors contribute to the analyst's negative outlook on the stock.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares